AU2014244020B2 - Mice expressing a limited immunoglobulin light chain repertoire - Google Patents

Mice expressing a limited immunoglobulin light chain repertoire Download PDF

Info

Publication number
AU2014244020B2
AU2014244020B2 AU2014244020A AU2014244020A AU2014244020B2 AU 2014244020 B2 AU2014244020 B2 AU 2014244020B2 AU 2014244020 A AU2014244020 A AU 2014244020A AU 2014244020 A AU2014244020 A AU 2014244020A AU 2014244020 B2 AU2014244020 B2 AU 2014244020B2
Authority
AU
Australia
Prior art keywords
human
mouse
light chain
immunoglobulin
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014244020A
Other languages
English (en)
Other versions
AU2014244020A1 (en
Inventor
Lynn Macdonald
John Mcwhirter
Andrew J. Murphy
Sean Stevens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/798,455 external-priority patent/US9796788B2/en
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2014244020A1 publication Critical patent/AU2014244020A1/en
Priority to AU2020203238A priority Critical patent/AU2020203238B2/en
Application granted granted Critical
Publication of AU2014244020B2 publication Critical patent/AU2014244020B2/en
Priority to AU2023202783A priority patent/AU2023202783A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2014244020A 2013-03-13 2014-03-13 Mice expressing a limited immunoglobulin light chain repertoire Active AU2014244020B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020203238A AU2020203238B2 (en) 2013-03-13 2020-05-19 Mice expressing a limited immunoglobulin light chain repertoire
AU2023202783A AU2023202783A1 (en) 2013-03-13 2023-05-04 Mice expressing a limited immunoglobulin light chain repertoire

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/798,455 US9796788B2 (en) 2010-02-08 2013-03-13 Mice expressing a limited immunoglobulin light chain repertoire
US13/798,455 2013-03-13
PCT/US2014/026040 WO2014160202A1 (en) 2013-03-13 2014-03-13 Mice expressing a limited immunoglobulin light chain repertoire

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020203238A Division AU2020203238B2 (en) 2013-03-13 2020-05-19 Mice expressing a limited immunoglobulin light chain repertoire

Publications (2)

Publication Number Publication Date
AU2014244020A1 AU2014244020A1 (en) 2015-09-24
AU2014244020B2 true AU2014244020B2 (en) 2020-06-04

Family

ID=50483561

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014244020A Active AU2014244020B2 (en) 2013-03-13 2014-03-13 Mice expressing a limited immunoglobulin light chain repertoire
AU2020203238A Active AU2020203238B2 (en) 2013-03-13 2020-05-19 Mice expressing a limited immunoglobulin light chain repertoire
AU2023202783A Pending AU2023202783A1 (en) 2013-03-13 2023-05-04 Mice expressing a limited immunoglobulin light chain repertoire

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020203238A Active AU2020203238B2 (en) 2013-03-13 2020-05-19 Mice expressing a limited immunoglobulin light chain repertoire
AU2023202783A Pending AU2023202783A1 (en) 2013-03-13 2023-05-04 Mice expressing a limited immunoglobulin light chain repertoire

Country Status (26)

Country Link
EP (4) EP2967013B1 (enExample)
JP (4) JP6529957B2 (enExample)
KR (2) KR102295842B1 (enExample)
CN (2) CN108611369B (enExample)
AU (3) AU2014244020B2 (enExample)
BR (1) BR112015022034B1 (enExample)
CA (1) CA2903698C (enExample)
CY (1) CY1121545T1 (enExample)
DK (2) DK3501272T5 (enExample)
ES (3) ES2712207T3 (enExample)
FI (1) FI3501272T3 (enExample)
HR (2) HRP20190706T1 (enExample)
HU (2) HUE044003T2 (enExample)
IL (2) IL240563B (enExample)
LT (2) LT3501272T (enExample)
MX (3) MX357308B (enExample)
PL (2) PL3501272T3 (enExample)
PT (2) PT3501272T (enExample)
RS (2) RS58669B1 (enExample)
RU (1) RU2689664C2 (enExample)
SG (2) SG11201506278RA (enExample)
SI (2) SI2967013T1 (enExample)
SM (2) SMT202300112T1 (enExample)
TR (1) TR201901668T4 (enExample)
WO (1) WO2014160202A1 (enExample)
ZA (2) ZA201505835B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
SMT201900372T1 (it) 2010-02-08 2019-09-09 Regeneron Pharma Topo con catena leggera comune
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
HUE068728T2 (hu) 2011-08-05 2025-01-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
PL3216871T3 (pl) 2011-10-17 2022-03-21 Regeneron Pharmaceuticals, Inc. Ograniczony łańcuch ciężki immonoglobuliny pochodzącej od myszy
EP2858487B1 (en) 2012-06-12 2019-10-23 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
RS57582B1 (sr) * 2013-02-20 2018-11-30 Regeneron Pharma Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
RU2016141307A (ru) 2014-03-21 2018-04-24 Регенерон Фармасьютикалз, Инк. Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
IL260526B2 (en) 2016-01-13 2023-10-01 Regeneron Pharma Rodents having an engineered heavy chain diversity region
WO2019067682A1 (en) * 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. BISPECIFIC ANTIGEN-BINDING MOLECULES BINDING TO TARGET STAPHYLOCOCCUS ANTIGEN AND COMPONENT COMPONENT, AND USES THEREOF
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
US12467062B2 (en) 2018-12-21 2025-11-11 Compass Therapeutics Llc Transgenic mouse expressing common human light chain
AU2020226445B2 (en) 2019-02-18 2025-05-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
EP3927153A1 (en) 2019-02-22 2021-12-29 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
AU2021283564B2 (en) 2020-06-02 2025-05-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
JP7758739B2 (ja) 2020-12-23 2025-10-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンカー改変型抗体をコードする核酸およびその使用
AU2021409906A1 (en) 2020-12-23 2023-06-15 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
CN114736927A (zh) * 2022-05-19 2022-07-12 东北大学 一种单抗克隆与表达载体的构建及应用
TW202430641A (zh) * 2023-01-18 2024-08-01 美商基利科學股份有限公司 人類免疫球蛋白二元輕鏈轉殖基因構築體及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012148873A2 (en) * 2011-04-25 2012-11-01 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies having a common light chain
WO2013022782A1 (en) * 2011-08-05 2013-02-14 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
US20130045492A1 (en) * 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
MXPA06000562A (es) * 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
EP2505058A1 (en) * 2006-03-31 2012-10-03 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
CA2652976C (en) 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
ITMI20071522A1 (it) * 2007-07-27 2009-01-28 Areta Internat S R L Vaccino idiotipico
RU2559524C2 (ru) * 2008-06-27 2015-08-10 Мерюс Б.В. Продуцирующие антитела млекопитающие, не являющиеся человеком
CN112690250B (zh) * 2008-12-18 2024-03-08 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
MX368932B (es) 2009-06-26 2019-10-22 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
SMT201900372T1 (it) * 2010-02-08 2019-09-09 Regeneron Pharma Topo con catena leggera comune
SI2480676T1 (sl) * 2010-06-22 2016-10-28 Regeneron Pharmaceuticals, Inc. Hibridna mišja lahka veriga
RU2612903C2 (ru) * 2010-08-02 2017-03-13 Ридженерон Фармасьютикалз, Инк. Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
RU2460287C1 (ru) * 2011-03-29 2012-09-10 Государственное образовательное учреждение высшего профессионального образования "Российский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО РГМУ Росздрава) Трансгенная мышь, предназначенная для моделирования состояний, угрожающих развитием синдрома внезапной сердечной смерти при дистрофин-дефицитной кардиомиопатии
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130045492A1 (en) * 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
WO2012148873A2 (en) * 2011-04-25 2012-11-01 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies having a common light chain
WO2013022782A1 (en) * 2011-08-05 2013-02-14 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice

Also Published As

Publication number Publication date
AU2020203238B2 (en) 2023-04-13
EP4218409A3 (en) 2023-08-30
EP3501272B1 (en) 2023-03-01
JP2016512034A (ja) 2016-04-25
CN105188357B (zh) 2018-04-24
JP2019213549A (ja) 2019-12-19
PL3501272T3 (pl) 2023-07-03
KR102424756B1 (ko) 2022-07-25
PT3501272T (pt) 2023-03-29
KR20210107911A (ko) 2021-09-01
WO2014160202A1 (en) 2014-10-02
CA2903698C (en) 2023-02-28
SG11201506278RA (en) 2015-09-29
HRP20190706T1 (hr) 2019-10-18
MX377146B (es) 2025-03-07
SMT202300112T1 (it) 2023-05-12
SMT201900196T1 (it) 2019-05-10
IL240563A0 (en) 2015-09-24
PL2967013T3 (pl) 2019-07-31
LT2967013T (lt) 2019-04-25
RU2019115237A (ru) 2019-06-11
KR20150126871A (ko) 2015-11-13
AU2014244020A1 (en) 2015-09-24
JP2019076109A (ja) 2019-05-23
AU2020203238A1 (en) 2020-06-11
MX2015012539A (es) 2016-06-28
CY1121545T1 (el) 2020-05-29
CN108611369B (zh) 2022-08-26
EP4545567A3 (en) 2025-08-13
DK2967013T3 (en) 2019-03-11
IL240563B (en) 2021-03-25
ZA201805369B (en) 2021-08-25
EP3501272A1 (en) 2019-06-26
HRP20230490T1 (hr) 2023-08-04
RU2015143110A (ru) 2017-04-18
DK3501272T3 (da) 2023-04-03
ES2712207T3 (es) 2019-05-09
SI2967013T1 (sl) 2019-03-29
IL280892B1 (en) 2023-01-01
ES2942413T3 (es) 2023-06-01
ES3013063T3 (en) 2025-04-10
CN105188357A (zh) 2015-12-23
IL280892B2 (en) 2023-05-01
IL280892A (en) 2021-04-29
FI3501272T3 (fi) 2023-04-06
HUE044003T2 (hu) 2019-09-30
CN108611369A (zh) 2018-10-02
DK3501272T5 (da) 2024-09-02
RS64185B1 (sr) 2023-05-31
JP7010902B2 (ja) 2022-02-10
SI3501272T1 (sl) 2023-05-31
KR102295842B1 (ko) 2021-08-31
TR201901668T4 (tr) 2019-02-21
PT2967013T (pt) 2019-04-03
RU2689664C2 (ru) 2019-05-28
AU2023202783A1 (en) 2023-05-25
EP4545567A2 (en) 2025-04-30
EP4218409A2 (en) 2023-08-02
BR112015022034A2 (pt) 2017-08-29
WO2014160202A4 (en) 2014-11-13
EP2967013A1 (en) 2016-01-20
HK1218493A1 (en) 2017-02-24
MX2020010837A (es) 2022-03-28
RS58669B1 (sr) 2019-06-28
SG10201801101QA (en) 2018-04-27
MX391010B (es) 2025-03-21
LT3501272T (lt) 2023-03-27
EP4218409B1 (en) 2025-02-12
BR112015022034B1 (pt) 2023-02-28
JP2020182490A (ja) 2020-11-12
ZA201505835B (en) 2019-09-25
EP4218409C0 (en) 2025-02-12
JP6790136B2 (ja) 2020-11-25
NZ711776A (en) 2021-09-24
MX357308B (es) 2018-07-04
JP6529957B2 (ja) 2019-06-12
CA2903698A1 (en) 2014-10-02
HUE061977T2 (hu) 2023-09-28
EP2967013B1 (en) 2019-01-16

Similar Documents

Publication Publication Date Title
US12389888B2 (en) Mice expressing a limited immunoglobulin light chain repertoire
AU2020203238B2 (en) Mice expressing a limited immunoglobulin light chain repertoire
US9969814B2 (en) Methods for making fully human bispecific antibodies using a common light chain
US20190090462A1 (en) Common light chain mouse
EP2701499A2 (en) Non-human animals expressing antibodies having a common light chain
EP2970437A1 (en) Common light chain mouse
HK40097135A (en) Mice expressing a limited immunoglobulin light chain repertoire
HK40097135B (en) Mice expressing a limited immunoglobulin light chain repertoire
HK40010381A (en) Mice expressing a limited immunoglobulin light chain repertoire
RU2812814C2 (ru) Мыши, экспрессирующие ограниченный репертуар легких цепей иммуноглобулина
HK40010381B (en) Mice expressing a limited immunoglobulin light chain repertoire
NZ711776B2 (en) Mice expressing a limited immunoglobulin light chain repertoire
HK1218493B (en) Mice expressing a limited immunoglobulin light chain repertoire

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ MCWHIRTER, JOHN; MACDONALD, LYNN; STEVENS, SEAN AND MURPHY, ANDREW J.

FGA Letters patent sealed or granted (standard patent)